コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 scle diffusive O(2) conductance (6.6 +/- 0.8 vs.
2 e 0.84 and 0.86 for predicting N1 or higher (vs.
3 of airway epithelia was unaltered by pH 7.4 vs.
4 recipients, and those with fewer than four (vs.
8 associated pneumonia (2.4/1,000 patient-days vs 0.6/1,000 patient-days) were all higher in the settin
9 =350 cells/muL (aHR, 0.51 [95% CI, .41-.63]) vs 0.93 [95% CI, .76-1.13] for CD4 count >350 cells/uL).
12 f 0.035 vs. 0.023 mm(-1) (P < 0.0003), 0.034 vs. 0.021 mm(-1) (P < 0.0001), and 0.033 vs. 0.019 mm(-1
13 , and a mean intrinsic fluorescence of 0.035 vs. 0.023 mm(-1) (P < 0.0003), 0.034 vs. 0.021 mm(-1) (P
15 [logMAR; Snellen equivalent, 20/200] in 2020 vs. 0.48 logMAR [Snellen equivalent, 20/60] in 2019; P =
16 ticipants for cpCD (0.32 [95% CI, 0.11-0.64] vs. 0.83 [95% CI, 0.69-0.93], respectively; P < 0.001).
17 DMT alone (adjusted least squares mean: -4.0 vs. -0.9 mm Hg; p = 0.006), a change that was associated
18 itt score, 0 [interquartile range {IQR} 0-1] vs 1 [IQR 0-2] in patients with any positive BDG test; P
19 year was similar between groups (O:E = 0.65 vs 1.00, P = 0.11 and O:E = 0.79 vs 1.00, P = 0.15, resp
21 lly ill patients than healthy patients (4.90 vs 1.48 hr) and was correlated with encephalopathy sever
22 , development of Clostridium difficile (4.5% vs 1.7%), and incidence density of ventilator-associated
23 compared with nepafenac-treated eyes (6 eyes vs. 1 eye; P = 0.04); no eyes showed IOP elevation of mo
24 median: 3.4; interquartile range: 3.25-3.55) vs. 1.23 +/- 0.23 (median: 1.2; interquartile range: 1.0
27 weeks (n = 523; 17% [300 mg] and 6% [150 mg] vs 10% [placebo]; 24% [150 mg] vs 28% [placebo]) and 1 t
29 occurred in 6.0% of infants in the DHA group vs 10.2% of infants in the placebo group (absolute diffe
30 tly fewer AR and asthma prescriptions (59.7% vs 10.8%) than the control group, and the probability of
31 lower rate of neurologic complications (3/61 vs 10/53 for DHCA; p < 0.05) but not complications in ot
32 e high diversity 17 species communities (~30 vs. 10 species), and colonists collectively produced 10
34 0(3) /uL, P = .019), C-reactive protein (198 vs. 107 mg/L, P = .010) and D-dimer (8.6 vs. 2.1 ug/mL,
35 ly associated with Crohn's development (100% vs 11%; P < 0.01) compared with mild or nonspecific infl
36 months, women had a lower risk of MACE (9.5% vs. 11.2%; adjusted hazard ratio: 0.77; 95% confidence i
37 chromosomal changes were found in 0/20 blood vs. 11/20 aqueous samples along with shorter DNA fragmen
39 interquartile range) pg/mL: 3285 (1697-6179) vs 1290 (758-3719); P < 0.001 and in patients developing
41 965 fmol/punch (IQR:691, 1166) in pregnancy vs 1406 fmol/punch (IQR:1053, 1859) postpartum (p=0.006)
42 sample size was 49% (72 vs. 148) and 25% (36 vs. 142) of original sample size for MAIC of benralizuma
46 .01), and experienced discrimination (29.0% vs 15.7%, P < .01) than whites (n = 121), blacks were on
49 og scale (-11.5 in the zoledronic acid group vs -16.8 in the placebo group; between-group difference,
50 ms was higher in patients with COVID-19 (26% vs. 16.3% in patients without COVID-19, p=0.0197; relati
53 ion to distensibility (79% vs 21%), CSA (82% vs 18%), and HPZ (60% vs 40%) than sphincter augmentatio
54 vs 26.4%, P < .01), perceived racism (55.5% vs 18.2%, P < .01), and experienced discrimination (29.0
55 d corn with 75% stover removal (17.6 +/- 2.8 vs 18.8 +/- 3.0 g CO(2)e MJ(-1)), but were notably lower
58 me (P > .05 for both 2010-2016 and 2003-2009 vs 1996-2002), and higher among black patients, those wi
59 16-18 years: aOR 0.75 [0.66-0.85]; p=0.0001 vs 2-5 years), and unknown HIV status of the mother (aOR
60 ital mortality (1.7% for uncemented fixation vs 2.0% for cemented fixation; HR, 0.94 [95% CI, 0.73-1.
61 FIT round compared to sigmoidoscopy at 1.4% vs 2.4% (OR, 0.57; 95% CI, 0.53-0.62) but higher after 3
63 discharge destination outside of home (20.5% vs 2.7%, P < 0.01) were significantly higher in the popu
64 ed with placebo (4.1 months [95% CI 3.3-4.8] vs 2.8 months [2.6-2.9]; HR 0.696 [95% CI 0.573-0.845];
66 sivity in the mucus obtained from adult pigs vs. 2-week old piglets showed better penetrability of th
67 198 vs. 107 mg/L, P = .010) and D-dimer (8.6 vs. 2.1 ug/mL, P = .004) levels, and lower nadir lymphoc
69 laque were smaller (median thickness, 1.9 mm vs. 2.6 mm; LBD, 7.1 mm vs. 8.6 mm) and located closer t
70 nd located closer to foveola (median, 2.0 mm vs. 2.8 mm) than those treated with the 15-mm plaque (P
71 nd 90-day clinically relevant bleeding (4.8% vs. 2.9%, p = 0.34) or major bleeding (3.6% vs. 1.6%, p
72 red with episodes with no complications (28% vs 20%, respectively; risk difference, 7% [95% CI, 5.8%-
73 subsequent eye at presentation (mean, 20/62 vs. 20/149; P < 0.001) and postoperative month 6 (mean,
75 .001) and postoperative month 6 (mean, 20/41 vs. 20/49; P = 0.03), but final VA was similar (20/36 vs
76 e and azithromycin in February to April 2020 vs 2019, and vs the top 10 most commonly prescribed drug
77 2%] of 66 patients in the intervention group vs 21 [32%] of 65 in the control group; adjusted odds ra
78 percent contribution to distensibility (79% vs 21%), CSA (82% vs 18%), and HPZ (60% vs 40%) than sph
79 k (assistant 69.5% vs 41.8%; associate 17.6% vs 21.0%; full professor 13.0% vs 37.2%) were not signif
82 e of local progression, 56% [range, 19%-91%] vs 22% [range, 12%-34%], respectively; P < .001) and con
83 patients received thromboprophylaxis (80.5% vs 22.3%) with lower rates of VTE for identical regimens
85 ter operation: 20.0% for uncemented fixation vs 22.8% for cemented fixation; HR, 0.95 [95% CI, 0.90-1
88 zation in significantly more patients (72.7% vs 23.1% p = 0.04) despite overall larger baseline defec
90 fection/fistulas, higher rates of SSOPI (46% vs 24%, P = 0.04) and reoperation (21% vs 6%, P = 0.03)
91 thout postoperative AF (incidence rate, 42.5 vs 25.0 per 1000 person-years; absolute RD at 5 years, 6
92 ed mortality, or discharge to hospice (37.2% vs 25.3%), extubation failure (12.3% vs 6.1%), tracheost
93 or care versus usual care: at 30 days (10.4% vs 26.3%; stabilized inverse probability of treatment we
94 ing higher levels of medical mistrust (40.0% vs 26.4%, P < .01), perceived racism (55.5% vs 18.2%, P
95 e of kidney failure (31.7% with intervention vs 27.3% with placebo; adjusted risk difference, 0.03; 9
97 d 6% [150 mg] vs 10% [placebo]; 24% [150 mg] vs 28% [placebo]) and 1 trial of nicotine replacement th
99 en had a primary diagnosis of pneumonia (41% vs 28%; p = 0.02) and less often asthma (8% vs 23%; p <
100 0.2; P = .58) or in 30-day mortality (34.7% vs 29.3%, respectively; hazard ratio, 1.3; 95% CI, 0.8-2
101 3.2 days, P < 0.01), readmission rate (29.1% vs 3.1%, P < 0.01), and discharge destination outside of
103 , P < 0.001) and on day 7 (7.8 +/- 3.7 %ID/g vs. 3.0 +/- 0.8 %ID/g, P = 0.006), though the efficiency
104 (9.6%) in the placebo group (incidence, 2.5 vs. 3.6 events per 100 person-years; hazard ratio, 0.69;
105 (median: 0.7; interquartile range: 0.4-1.15) vs. 3.63 +/- 0.29 (median: 3.7; interquartile range: 3.4
106 0.5 +/- 4.1 percentage injected dose [%ID]/g vs. 3.8 +/- 0.9 %ID/g, P < 0.001) and on day 7 (7.8 +/-
109 nosis of PSC at an age younger than 40 years vs 31% of patients who received a diagnosis when older t
110 an [interquartile range], 11 [8-15] cm H(2)O vs. 31.5 [30-36] cm H(2)O; P < 0.0001), whereas other va
111 7 months (95% confidence interval 38.5-75.5) vs 33 months (95% confidence interval 20.3-45.7), P = 0.
112 other career development award funding (55% vs 33%, P = 0.03) and more publications [median 70 (inte
113 likely to have systemic hypertension (17.7% vs. 33.8%, P < 0.001), tumor location in the macula (57.
114 longest follow-up available (432/1,375 [31%] vs 330/1,295 [25%]; risk ratio, 1.24; 95% CI, 1.10-1.39;
115 ; 95% CI, 0.224-1.297) and at 60 days (16.7% vs 34.7%; stabilized inverse probability of treatment we
118 ular outflow tract (LVOT) obstruction (63.3% vs 36.7%, P = 0.01), to be smokers (17% vs 6.9%, P = 0.0
121 sociate 17.6% vs 21.0%; full professor 13.0% vs 37.2%) were not significant after adjusting for caree
122 GG (63.1% vs. 56.7%) and CG genotypes (33.1% vs. 38.9%) and G allele of rs755622 (79.6% vs. 76.1%, re
123 09) and post-consolidation (414 [90%] of 460 vs 386 [88%] of 438) assessments and were similar betwee
124 in oxygen tension gradient (16 mm Hg [sd, 6] vs 39 mm Hg SD, 11]; p < 0.001) and in the relationship
125 CI, 79.0%-99.2%) with abbreviated breast MRI vs 39.1% (95% CI, 22.2%-59.2%) with DBT (P = .001) and s
128 t DBT examination (6.1 per 1000 examinations vs 4.4-5.7 per 1000 examinations with at least one prior
129 failure (12.3% vs 6.1%), tracheostomy (21.6% vs 4.5%), development of Clostridium difficile (4.5% vs
130 < 0.01), lactate [1.1 mmol/L (IQR: 1.0-1.6) vs 4.6 mmol/L (IQR: 2.8-8.0), P < 0.01], and fraction of
133 6.1%, respectively), while CC genotype (3.8% vs. 4.4%) and C allele (20.4% vs. 23.9%) carriers were t
137 ere high at post-induction (431 [84%] of 513 vs 405 [80%] of 509) and post-consolidation (414 [90%] o
138 males at each academic rank (assistant 69.5% vs 41.8%; associate 17.6% vs 21.0%; full professor 13.0%
139 of symptoms (16/80 patients [19.5%] in 2020 vs. 41/106 patients [36.9%] in 2019; P = 0.005), and a g
140 raction of inspired oxygen [25% (IQR: 21-31) vs 42% (IQR: 30-80), P < 0.01] differed between survivor
141 rowth in all 3 sets of blood cultures (15.4% vs 45.1%; P = .005) and had less severe clinical present
144 eight reductions 1 year after surgery (44.6% vs. 46.6%), 8 diabetes remitters had significant reducti
146 mptoms less often than younger children (29% vs. 48%; p=0.01) or adolescents (29% vs. 60%; p<0.0001).
147 epithelialization within 3.56 +/- 1.78 weeks vs 5.87 +/- 2.20 weeks (p = 0.01) and achieved complete
148 enin activity and serum aldosterone were 6.8 vs. 5.5 ng/mL/h (p = 0.002) and 654 vs. 473 pg/mL (p = 0
152 levated self-report scores for anxiety (55.2 vs. 50.0), depression (50.2 vs. 46.1), and somatization
153 7 yr; p < 0.0001), predominantly male (73.1% vs 53.9%; p < 0.0001), and more frequently treated in te
154 DT era patients were of older mean age (48.9 vs. 53.8 years, P = 0.002) and were more likely to have
157 and ACS patients carried rs755622 GG (63.1% vs. 56.7%) and CG genotypes (33.1% vs. 38.9%) and G alle
160 ter Universities Osteoarthritis Index (-37.5 vs -58.0, respectively; between-group difference, 20.5 [
164 (37.2% vs 25.3%), extubation failure (12.3% vs 6.1%), tracheostomy (21.6% vs 4.5%), development of C
165 3.3% vs 36.7%, P = 0.01), to be smokers (17% vs 6.9%, P = 0.04), and had a higher ECV (30% vs 28%, P
166 changes in bone marrow lesion size (-33 mm2 vs -6 mm2; between-group difference, -27 mm2 [95% CI, -1
167 (p=0.28), and SCr elevations occurred in 20% vs. 6% (p=0.06) of patients with SRI versus those withou
168 ose with early/mild ILA at enrollment (63.3% vs. 6.1%; P < 0.0001).Conclusions: Rare and common envir
170 Trauma patients were younger (49.0 +/- 21.6 vs 60.6 +/- 18.7 yr; p < 0.0001), predominantly male (73
174 en were older (mean +/- SD age: 67.8 +/- 8.9 vs. 66.1 +/- 8.2 years; p < 0.001) and more likely to ha
175 0.001), tumor location in the macula (57.4% vs. 67.5%, P = 0.01), subretinal fluid on OCT (33.3% vs.
176 eta-states (meta-state numbers, 75.8 +/- 7.9 vs 68.8 +/- 12.0, p = 0.043 FDR-corrected) and changes f
177 ad higher peak white blood cell counts (15.8 vs 7 x 10(3) /uL, P = .019), C-reactive protein (198 vs.
179 patients than the two-tiered testing (82.4% vs 70.6% in the training set, 66.7% vs 60.0% in the vali
180 %, P = 0.01), subretinal fluid on OCT (33.3% vs. 70.7%, P = 0.01), and greater extent of overlying li
181 to another (meta-state changes, 77.1 +/- 7.3 vs 71.2 +/- 11.0, p = 0.043 FDR-corrected) than beginner
183 n C-reactive protein [138 mg/L (IQR: 83-179) vs 73 mg/L (IQR: 12-98), P < 0.01), lactate [1.1 mmol/L
184 s those of the general endoscopists were 88% vs 73% accuracy, 93% vs 72% sensitivity, and 83% vs 74%
187 % vs. 38.9%) and G allele of rs755622 (79.6% vs. 76.1%, respectively), while CC genotype (3.8% vs. 4.
188 ter 25 h shifts (predicted probability 99.4% vs 78.8%), whereas there was no relevant difference betw
189 ficant pathological regression (TRG1-2 = 44% vs 8%, P < 0.001) and a trend to tumor downstaging as co
193 e surgeries coded as complex (15.6% of cases vs 8.8%, P < .0001), and surgeries exceeding 30 minutes
194 an thickness, 1.9 mm vs. 2.6 mm; LBD, 7.1 mm vs. 8.6 mm) and located closer to foveola (median, 2.0 m
196 (52.18 vs. 40.11, p = 0.001), insulin (19.35 vs. 8.80 mIU/L, p < 0.001) and HOMA-IR index (6.48 to 2.
197 with zoledronic acid than with placebo (96% vs 83%, respectively) and consisted mainly of acute reac
198 or those on DTG-based treatment (61/92 [66%] vs 84% [391/465] P < 0.001, P for interaction by regimen
201 or those on EFV-based treatment (60% [12/20] vs 86% [214/248], P = 0.002) and for those on DTG-based
202 3-year risk of subsequent admissions (72.6% vs 86.4%, p < 0.001) than those with NOM, with hazard ra
206 88; p < 0.001) and all-cause-mortality (7.6% vs. 9.7%; adjusted hazard ratio: 0.61; 95% confidence in
209 specificity was 86.7% (95% CI, 84.8%-88.4%) vs 97.4% (95% CI, 96.5%-98.1%), respectively (P < .001).
210 To do this we screened the E90K GnRHR mutant vs. a library of 645,000 compounds using a cell-based ca
211 sis of DEG that were higher or lower in PVEC vs. ABEC identified "Nervous system development" and "Re
213 of definite NASH (ADH1B*2: OR, 0.80; P < .01 vs ADH1B*1: OR, 0.96; P = .036) and a reduced risk of an
214 of 4 or higher (ADH1B*2: OR, 0.83; P = .012 vs ADH1B*1: OR, 0.96; P = .048) (P < .01 for the differe
215 current density of 65.8 mA.cm(-2) at -1.8 V vs. Ag/Ag(+) is observed with a Faradaic efficiency to f
216 natures obtained from the in vitro model (CS vs. air) with a published data set from human epithelial
217 erformed a transcriptomics analysis of APOE4 vs. APOE3 expression in the entorhinal cortex (EC) and p
220 ected HLA-A*0201 positive symptomatic (SYMP) vs. asymptomatic (ASYMP) individuals and HLA-A*0201 tran
221 ols, < 0.0001-0.03); improvement at month 18 vs baseline was higher in Cit-B12 than placebo (33% vs 1
222 ling exponents of whole-plant metabolic rate vs body size numerically converge onto 1.0 after water c
226 injection time, injection method (pulsatile vs. continuous), or concomitant intravitreal melphalan u
227 ecreases in HBsAg to below 1 IU/mL (P < .001 vs control) and HBsAg seroconversion (P = .046 vs contro
236 values calculated from cellulose delta(18) O vs crown fluxes were remarkably consistent; both varied
237 o showed significantly increased sensitivity vs cytology when comparing regression vs persistence/pro
239 lites that differed between patients who did vs did not develop ACLF and patients who did vs did not
240 vs did not develop ACLF and patients who did vs did not die during hospitalization and within 30 days
241 g to anticipation of and performance on easy vs. difficult working memory tasks with emotional stimul
242 input within the dendritic branch (proximal vs distal), (2) the strength of the input pattern (subth
246 AL growth was analyzed relative to treated vs fellow eye, contact lens (CL) vs intraocular lens (IO
248 ters and their combinations to predict GGG 1 vs >1, using logistic regression with a nested leave-pai
249 200 (56%), patients with current CD4 351-500 vs >500 cells/muL had an aIRR of 1.22 (95% CI, .93-1.60)
250 ble analysis, endotracheal tube size (<= 7.5 vs >= 8.0) was significantly associated with patients ex
251 between patients on a GFD with new-onset CD vs healthy children were associated with nutrient and fo
255 stic performance for identifying none-to-low vs. intermediate-to-high AD neuropathologic change (ADNC
256 intervention periods, respectively (baseline vs intervention and postintervention, P = .001 and P = .
257 to treated vs fellow eye, contact lens (CL) vs intraocular lens (IOL), visual acuity (VA) outcome, a
259 ctives relative to nouns (e.g., "black lamp" vs. "lamp black") makes visual context information avail
260 , polymer nanopores), architecture (branched vs linear), functional groups (coordinating or ionic), s
261 elevant variables measured (including short- vs. long-term sexual strategy, temporal discounting, the
264 riginal sample size for MAIC of benralizumab vs. mepolizumab and benralizumab vs. dupilumab, respecti
265 cid site density and distribution (in micro- vs. mesopores), and catalytic activity suggest nearly in
266 ferent motor-learning tasks, i.e. model-free vs. model-based learning tasks, and their possible diffe
268 001, and p = 0.001 for sacituzumab govitecan vs naked antibody, and sacituzumab govitecan vs control-
269 and LZP inhibited responses to fearful faces vs. neutral faces within the centromedial amygdala (cmA)
271 (26 [63%] of 41 patients with Zika infection vs nine [16%] of 55 with chikungunya infection; p<=0.000
273 9); P < 0.001 and in patients developing CPC vs no-CPC (area under the curve), median (interquartile
274 ta set from human epithelial brushes (smoker vs. non-smoker) revealed a high degree of similarity bet
275 y requiring renal replacement therapy in SOT vs. non-SOT patients (37% vs. 27%; RR [95% CI]: 1.34 [0.
282 and duration of GERD (AuROC for GERD, 0.579 vs range for other tools, 0.660-0.695), and predicted ri
283 adverse event rates associated with IV iron vs red cell transfusion and discuss using first-line IV
284 adults comparing Spanish regions using PCV13 vs regions using PPV23 vaccine was also analyzed for 201
288 cose tolerance in aged mice fed a chow (~30% vs. saline) or HF (~50% vs. saline) diet and young mice
289 tions between the stage of syphilis (primary vs secondary) and behavioral data collected by computer-
292 for pointwise rates (medical therapy, 26.1% vs. SLT, 19.0%; RR, 1.37; 95% CI, 1.33-1.42; P < 0.001).
293 mycin in February to April 2020 vs 2019, and vs the top 10 most commonly prescribed drugs in the same
294 Deltacreatinine post PCI in the DR group vs. the control group did not show any difference (DR: 0
295 tients and images) values for the CAD system vs those of the general endoscopists were 88% vs 73% acc
296 d components of the GCX under DF conditions, vs UF conditions, with undifferentiated levels of CTC-re
298 ce rate ratios (IRRs) for black and Hispanic vs white populations in 6 cities in the United States (2
300 om patients with sporadic CRC colonized with vs without CoPEC by quantitative reverse-transcription p